Welcome to our dedicated page for Veru SEC filings (Ticker: VERU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veru Inc. filings document regulatory disclosures for a Wisconsin biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under VERU. Recent 8-K reports cover financial results, clinical program updates, material agreements, settlement of promissory-note obligations, security-holder rights, and capital-structure actions, including the completed 1-for-10 reverse stock split.
Proxy and annual-meeting records describe board elections, auditor ratification, executive compensation votes, and amendments to the 2018 Equity Incentive Plan. The filing record also includes Nasdaq listing-compliance disclosures and exhibits tied to Veru’s enobosarm and sabizabulin development programs.
Veru Inc. reported a narrower net loss for fiscal 2026 first quarter while advancing its obesity drug pipeline. Net loss from continuing operations was $5.33 million versus $1.81 million a year ago, but total net loss improved to $5.33 million from $8.95 million, which previously included discontinued operations. Operating expenses fell sharply to $5.42 million from $10.94 million, reflecting lower research and development and general and administrative spending. Cash, cash equivalents and restricted cash increased to $33.0 million from $15.8 million at September 30, 2025, helped by $23.37 million of net cash provided by financing activities.
Veru highlighted positive Phase 2b QUALITY data for obesity drug enobosarm in combination with semaglutide, showing greater fat loss and preservation of lean mass in older patients with obesity. The company received FDA feedback outlining regulatory pathways based on incremental weight loss and physical function or bone mineral density benefits. Veru plans a Phase 2b PLATEAU trial in about 200 older patients with obesity initiating semaglutide, with a 68‑week primary endpoint and an interim analysis at 34 weeks, expected to start in the first quarter of calendar 2026 and yield interim results in the first quarter of calendar 2027.
Veru Inc. is asking shareholders to approve several governance and compensation items at its March 12, 2026 annual meeting in Miami. Shareholders of record on January 14, 2026, when 16,050,320 common shares were outstanding, may vote in person, online, by phone, or by mail.
The proxy seeks to elect six incumbent directors, ratify Cherry Bekaert LLP as auditor for the year ending September 30, 2026, approve an amendment to the 2018 Equity Incentive Plan, hold a non-binding advisory vote on executive pay, and approve a potential adjournment of the meeting. The equity plan amendment would raise authorized shares from 2,600,000 to 5,850,000, increase the annual award limit for most participants to 750,000 shares and for non-employee directors to 120,000 shares, and could raise fully diluted overhang from 7.4% to 13.9%.
The filing also describes prior restatements and material weaknesses in internal control disclosed in earlier reports, notes that RMS US LLP’s 2023 audit opinion included substantial doubt about Veru’s ability to continue as a going concern, and outlines a new clawback policy and detailed pay-versus-performance data showing continuing net losses and a declining total shareholder return.
Veru Inc. is registering 750,000 additional shares of common stock for issuance under its 2018 Equity Incentive Plan. These shares come from a shareholder‑approved plan amendment and reflect the company’s 1‑for‑10 reverse stock split that became effective on August 8, 2025, which reduced the original 7,500,000 additional plan shares to 750,000.
The filing is a Form S‑8, which is used to register shares that may be granted to employees, directors and other service providers as equity compensation. Veru also lists prior charter amendments increasing authorized common stock and the articles of amendment that implemented the reverse stock split.
Veru Inc. has transformed into a late clinical stage biopharmaceutical company after selling its FDA-approved FC2 Female Condom business on December 30, 2024, a strategic shift that had a major effect on operations and financial results. The company now focuses on two drug candidates: enobosarm for obesity patients receiving GLP-1 receptor agonists and sabizabulin for inflammation in atherosclerotic cardiovascular disease.
Enobosarm, an oral selective androgen receptor modulator, produced positive Phase 2b QUALITY trial results in older obese patients on semaglutide, delivering a 100% relative reduction in lean mass loss at the 3 mg dose (p<0.001) and shifting weight loss almost entirely to fat. Extension data showed that enobosarm monotherapy reduced weight and fat regain after semaglutide was stopped, while maintaining a favorable safety profile. Veru plans a Phase 2b PLATEAU study in about 200 patients with obesity starting GLP-1 therapy and is developing a modified-release oral formulation it expects to use in Phase 3.
Sabizabulin, a microtubule disruptor targeting inflammatory pathways, is being advanced for stable coronary artery disease following an FDA pre-IND meeting, with an initial Phase 2 study planned to lower high-sensitivity C-reactive protein. Veru highlights risks from its history of losses, current lack of commercial revenue, dependence on external funding and Nasdaq listing compliance, and notes a 1-for-10 reverse stock split effective August 8, 2025. The board oversees an enterprise-wide cybersecurity program, and the company reports no cybersecurity threats that have materially affected its business to date.
Veru Inc. released a press release announcing its financial results for the year ended September 30, 2025, and made that release available to investors as an exhibit to a current report. The press release is included as Exhibit 99.1.
The company furnished this information rather than formally filing it, so it is not treated as filed under certain securities law provisions or automatically included in other reports unless it is specifically referenced there.
Veru Inc. announced an underwritten public offering of 8,400,000 shares of common stock (or pre-funded warrants in lieu of shares), each sold together with Series A and Series B warrants to purchase up to 8,400,000 shares each, at a combined public offering price of $3.00 per share and accompanying warrants.
The company expects net proceeds of approximately $23.4 million, with closing anticipated on or about October 31, 2025, subject to customary conditions. The offering is made off Veru’s effective Form S-3 shelf. Pre-funded warrants are immediately exercisable at $0.001 per share, with holder ownership limits of 4.99% (or 9.99% upon election). Series A warrants are immediately exercisable at $3.00 and expire five years from issuance. Series B warrants are immediately exercisable at $3.00 and expire on the earlier of three years from issuance or achievement of specified clinical and stock price thresholds. Veru and its directors and officers agreed to a 90‑day lock-up, subject to exceptions.
Veru Inc. launched a primary offering of 1,400,000 shares of common stock and pre-funded warrants to purchase up to 7,000,000 shares, together with Series A warrants to purchase up to 8,400,000 shares and Series B warrants to purchase up to 8,400,000 shares. The combined public offering price is $3.00 per share with warrants (or $2.999 with a pre-funded warrant).
Pre-funded warrants are immediately exercisable at $0.001 per share. Series A and Series B warrants are immediately exercisable at $3.00 per share; Series A expire five years from issuance. Series B expire on the earlier of the third anniversary or 45 days after specified clinical and stock-price conditions are met. The company does not intend to list the warrants.
Veru estimates net proceeds of approximately $23.4 million, to fund development of enobosarm, primarily the planned Phase 2b PLATEAU obesity study, and for working capital and general corporate purposes. Shares outstanding were 14,650,392 as of June 30, 2025; this is a baseline figure, not the amount being offered.
Veru Inc. filed a preliminary prospectus supplement for a primary offering of common stock and, in lieu of shares for certain investors, pre-funded warrants, together with accompanying Series A and Series B common stock warrants. The filing also covers the shares issuable upon exercise of these warrants.
The company states it will receive the proceeds from this offering and intends to use them primarily to fund the planned Phase 2b PLATEAU clinical study of enobosarm in combination with GLP‑1 RA therapy, as well as for working capital and general corporate purposes. Pre-funded warrants are immediately exercisable at $0.001 per share. Series A warrants are immediately exercisable and expire five years from issuance. Series B warrants are immediately exercisable and expire on the earlier of a data/price milestone or three years. The warrants will not be listed, which may limit liquidity.
Shares outstanding were 14,650,392 as of June 30, 2025. The company effected a 1‑for‑10 reverse stock split on August 8, 2025. Veru’s common stock last closed at $3.65 on October 28, 2025.
Michael L. Rankowitz, a director of VERU Inc. (VERU), reported an acquisition of equity-linked compensation on 10/01/2025. The filing records the grant of 7,000 common stock options with an exercise price of $3.89, exercisable beginning 10/01/2026 and expiring 10/01/2035.
The options vest in three equal installments, with one-third vesting on each of 10/01/2026, 10/01/2027, and 10/01/2028. After the reported transaction the filing shows beneficial ownership of 7,000 shares/options held directly. The Form 4 was signed via power of attorney by Phil R. Greenberg on 10/03/2025.
Hyun Grace, a director of VERU Inc. (VERU), reported an acquisition of 3,000 non‑derivative shares resulting from the exercise/issuance of options on 10/01/2025. The options have an exercise price of $3.89, are exercisable beginning 10/01/2026 and expire on 10/01/2035. Following the reported transaction the filing shows 3,000 shares beneficially owned directly by the reporting person.
The form discloses a vesting schedule: one‑third of the options vest on each of 10/01/2026, 10/01/2027 and 10/01/2028. The Form 4 was signed on behalf of the reporting person by power of attorney on 10/03/2025. All details above are taken directly from the filing and no additional inferences are made.